Search results
Showing 1 to 9 of 9 results for testosterone
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
Relugolix for treating hormone-sensitive prostate cancer (TA995)
Evidence-based recommendations on relugolix (Orgovyx) for hormone-sensitive prostate cancer in adults.
This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.
This quality standard covers managing prostate cancer in people referred to secondary care or having follow-up for prostate cancer in primary care. It describes high-quality care in priority areas for improvement.
View quality statements for QS91Show all sections
Sections for QS91
- Quality statements
- Quality statement 1: Discussion with a named nurse specialist
- Quality statement 2: Treatment options
- Quality statement 3: Combination therapy
- Quality statement 4: Managing adverse effects of treatment
- Quality statement 5: Hormone-relapsed metastatic prostate cancer
- Update information
- About this quality standard
Autism spectrum disorder in adults: diagnosis and management (CG142)
This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder (autism, Asperger’s syndrome and atypical autism) in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.
Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a docetaxel-containing regimen.
Thousands of people could benefit from a new oral hormone therapy for advanced hormone sensitive prostate cancer.
NICE has outlined what aspects of menopause care will be updated in upcoming guidance, including areas where more research is needed.